Kyverna Therapeutics is trading 5.21% lower at $6.18, with biotech-sector weakness a possible contributor.
- No new company-specific announcement explaining the October 2, 2026 move was identified; the latest listed release is September 24 clinical data.
- Biotech was 2.01% lower pre-market, while broader markets were higher, pointing to sector pressure rather than a general-market decline; this is not a confirmed direct cause.